What question did this study set out to answer?

To evaluate the neuroprotective mechanisms, preclinical evidence, and therapeutic potential of angiotensin receptor blockers (ARBs) for treating acute and chronic brain disorders.

October 31, 2014American Journal of HypertensionOpen Access

Neuroprotective Effects of Angiotensin Receptor Blockers

View Full Paper

Ask AI

Bookmark

Why the study?

Do Angiotensin II receptor blockers (ARBs) provide neuroprotective effects in patients with brain disorders?

Population

Patients with brain disorders and pre-clinical models

Design

Review

Authors

SVSonia VillapolHouston Methodist JSJuan M. SaavedraConsejo Superior de Investigaciones Científicas

Discussion

Member takes

Implication

ARBs should not yet be prescribed for neuroprotection; leaves open whether RCTs will confirm preclinical and epidemiological signals in Alzheimer's and stroke.

Key Points

To evaluate the neuroprotective mechanisms, preclinical evidence, and therapeutic potential of angiotensin receptor blockers (ARBs) for treating acute and chronic brain disorders.
Synthesized data from in vitro neuronal, glial, and cerebrovascular cell cultures subjected to inflammatory and apoptotic insults.
Reviewed preclinical animal models of stroke, traumatic brain injury, Alzheimer's disease, and Parkinson's disease alongside epidemiological and clinical observations.
ARBs attenuate neuroinflammation, apoptosis, and blood-brain barrier breakdown while preserving cerebral blood flow via AT1 receptor blockade and PPARγ activation.
Epidemiological and clinical evidence associates ARB administration with slowed Alzheimer's disease progression and reduced post-stroke cognitive decline.
Individual ARB compounds exhibit substantial pharmacological heterogeneity, yet direct head-to-head comparative analyses and controlled clinical trials remain lacking.

Structured PICO

Do Angiotensin II receptor blockers (ARBs) provide neuroprotective effects in patients with brain disorders?

Population

Patients with brain disorders (including stroke, traumatic brain injury, Alzheimer's, and Parkinson's disease) and pre-clinical models (cultured neurons, astrocytes, microglial, endothelial cerebrovascular cells, and animal models)

Intervention

Angiotensin II receptor blockers (ARBs)

Outcome

Neuroprotection (including amelioration of inflammatory and apoptotic responses, protection of cerebral blood flow, maintenance of blood brain barrier function, and decreased cerebral hemorrhage/neuronal injury)

Pre-clinical and epidemiological data suggest ARBs have neuroprotective properties, highlighting their potential for repurposing in the treatment of brain disorders pending controlled clinical trials.

Limitations

The complete pharmacological spectrum and therapeutic efficacy of individual ARBs have never been systematically compared
The neuroprotective efficacy of these compounds has not been rigorously determined in controlled clinical studies

Cite This Study

Villapol et al. (2014) studied this question.

synapsesocial.com/papers/6a7045f226a7f98052dcc5c9 https://doi.org/10.1093/ajh/hpu197

View Full Paper

Ask AI

Bookmark

Implication

ARBs should not yet be prescribed for neuroprotection; leaves open whether RCTs will confirm preclinical and epidemiological signals in Alzheimer's and stroke.

Neuroprotective Effects of Angiotensin Receptor Blockers

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Neuroprotective Effects of Angiotensin Receptor Blockers

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider